Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A spinal cord ependymoma that is characterized by MYCN amplification.
Biomarker and diagnostic research for spinal ependymoma, MYCN-amplified has been reported in the published literature.
No clinical trials have been registered for spinal ependymoma, MYCN-amplified.
6 publications have been identified in PubMed for spinal ependymoma, MYCN-amplified. Research spans Basic Science / Preclinical (33%), Other (17%), and Diagnostic / Biomarker (17%).
Corrêa DG (2025). [PMID: 39964369](https://pubmed.ncbi.nlm.nih.gov/39964369/). *Neurol Sci*. [Other]
Liu W (2025). [PMID: 41160379](https://pubmed.ncbi.nlm.nih.gov/41160379/). *Cell Oncol (Dordr)*. [Basic Science / Preclinical]
Zhou MH (2025). [PMID: 39761545](https://pubmed.ncbi.nlm.nih.gov/39761545/). *J Neurosurg Case Lessons*. [Case Report / Case Series]
Engertsberger L (2024). [PMID: 39713042](https://pubmed.ncbi.nlm.nih.gov/39713042/). *Neurooncol Adv*. [Basic Science / Preclinical]
Topel G (2024). [PMID: 38555652](https://pubmed.ncbi.nlm.nih.gov/38555652/). *Ann Diagn Pathol*. [Epidemiology / Natural History]
Mohan D (2024). [PMID: 38411836](https://pubmed.ncbi.nlm.nih.gov/38411836/). *Hum Cell*. [Diagnostic / Biomarker]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 3:33 AM UTC